Alexion Pharmaceuticals, Inc. (ALXN) Short Interest Down 33.3% in February

Sheri Evans
March 15, 2018

Honeywell International Inc. grew its stake in shares of Alexion Pharmaceuticals, Inc. Clearbridge Investments LLC now owns 3,541,871 shares of the biopharmaceutical company's stock valued at $423,572,000 after buying an additional 307,117 shares during the period. The institutional investor held 13,001 shares of the consumer non-durables company at the end of 2017Q3, valued at $1.33M, up from 7,600 at the end of the previous reported quarter. It fall, as 36 investors sold Alexion Pharmaceuticals, Inc. shares while 174 reduced holdings. The stock increased 1.02% or $1.23 during the last trading session, reaching $122.31. About 759,993 shares traded.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) received a Buy rating from 5 analysts. It has underperformed by 34.82% the S&P500.The move comes after 8 months positive chart setup for the $27.02 billion company.

Since September 28, 2017, it had 0 buys, and 6 sales for $10.26 million activity. 6,079 shares were sold by Clancy Paul J, worth $707,048 on Tuesday, February 6. $2.66M worth of Facebook, Inc. (NYSE:EOG) for 100,276 shares. Finally, Invictus RG purchased a new position in shares of Alexion Pharmaceuticals in the third quarter valued at about $202,000.

Among 54 analysts covering Facebook (NASDAQ:FB), 50 have Buy rating, 2 Sell and 2 Hold. The stock has "Buy" rating by Robert W. Baird on Friday, November 17. Needham maintained Facebook, Inc. (NYSE:FCX) is 23. Credit Suisse has "Neutral" rating and $201 target. SunTrust Banks set a $172.00 target price on Alexion Pharmaceuticals and gave the company a "buy" rating in a research note on Monday, February 12th. (NYSE:NKE) earned "Outperform" rating by Credit Suisse on Friday, September 25. On Friday, October 28 the stock rating was upgraded by FBR Capital to "Mkt Perform". The firm earned "Overweight" rating on Tuesday, June 7 by Morgan Stanley. As per Saturday, August 29, the company rating was downgraded by Vetr. $192,028 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by HANTSON LUDWIG. Jefferies has "Buy" rating and $110.0 target. The company was downgraded on Thursday, October 5 by Citigroup. Looking at some alternate time periods, the 12 month price index is 1.48989, the 24 month is 1.91979, and the 36 month is 0.99206.

Investors sentiment decreased to 2 in 2017 Q3. Its up 0.17, from 1.07 in 2017Q2. 78 funds opened positions while 358 raised stakes. Another trade for 113,687 shares valued at $20.89 million was made by Menear Craig A on Wednesday, February 21. The institutional investor held 3,807 shares of the technology company at the end of 2017Q3, valued at $651,000, down from 8,240 at the end of the previous reported quarter. (NYSEAMERICAN:EVBN). Bessemer Grp has 0% invested in Evans Bancorp, Inc. (NYSE:DPLO) is 0.557680. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. Parametric Port Associates Ltd has 0.05% invested in McCormick & Company, Incorporated (NYSE:MKC). (NYSE:NKE) or 750,858 shares. Oakworth Capital accumulated 0.07% or 2,000 shares. Mu Investments Com reported 87,300 shares. Drw Limited Liability Com has 2,700 shares for 0.12% of their portfolio. Quantitative Systematic Strategies Ltd Llc owns 2,339 shares for 0.09% of their portfolio. Manufacturers Life Insur The reported 354,029 shares or 0.02% of all its holdings. Baker Bros Lp owns 8.55M shares for 9.73% of their portfolio. Symphony Asset Ltd Liability reported 11,883 shares. Silvercrest Asset Grp, New York-based fund reported 60,471 shares. Capital Research invested in 0.01% or 144,063 shares. (NYSE:NKE). Ramsay Stattman Vela & Price has 2.78% invested in NIKE, Inc.

Analysts await NIKE, Inc. They expect $3.39 EPS, up 13.00% or $0.39 from last year's $3 per share. ALXN's profit will be $283.75M for 24.35 P/E if the $1.28 EPS becomes a reality. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.39.

University strikes to continue despite proposed deal between union leaders and employers
As of 1pm on Tuesday 13, 43 branches of the UCU had campaigned for the committee to reject the proposal. Dozens of staff at the open university are striking over the threat of cuts to their pensions.

Who will design Meghan Markle's wedding dress?
In the past, Harry and Meghan's relationship may not have been accepted by the monarch because Meghan is a divorcée. The shoes are a closet staple for Reese Witherspoon, first lady Melania Trump, and more boldface names.

Ford's recall covers 1.4 million cars with steering wheel flaw
Ford says the recall covers more than 1.3 million in North America with 62,479 sold in Canada and another 14,172 in Mexico. The affected models are the Ford Fusion and the Lincoln MKZ , both from model years 2014-2018.

Bridges Investment Management Inc, which manages about $695.30 million and $778.44 million US Long portfolio, decreased its stake in Express Scripts Holding Co Com (NASDAQ:ESRX) by 5,262 shares to 45,665 shares, valued at $2.89 million in 2017Q3, according to the filing. It also reduced its holding in Restaurant Brands Intl Inc (Put) by 21,500 shares in the quarter, leaving it with 41,000 shares, and cut its stake in Marathon Oil Corp (NYSE:MRO). Alexion Pharmaceuticals Inc now has $26.84 billion valuation. The analyst recommendations from a month ago are 6 Buy, 1 Overweight, 0 Sell, 14 Hold and 2 Underweight. Therefore 71% are positive. Greenleaf Trust reported 0% in Alexion Pharmaceuticals, Inc. Main Street Llc holds 0.04% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, December 11 with "Buy" rating. Stifel Nicolaus has "Buy" rating and $182 target. The rating was maintained by Argus Research on Wednesday, August 17 with "Buy". (NASDAQ:ALXN) by 1.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). (NASDAQ:ALXN) earned "Outperform" rating by Raymond James on Thursday, January 4. BidaskClub raised Alexion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Wednesday, December 27th. JP Morgan maintained the stock with "Neutral" rating in Thursday, October 12 report. BMO Capital Markets lifted their price objective on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the stock an "outperform" rating in a research note on Friday, February 9th. The firm has "Buy" rating by Argus Research given on Thursday, October 22. TIAA CREF Investment Management LLC boosted its position in shares of Alexion Pharmaceuticals by 12.1% during the fourth quarter. (NASDAQ:ALXN) to report earnings on April, 26.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.25, from 1.4 in 2017Q2.

Other hedge funds have also recently added to or reduced their stakes in the company. That compares with the recent volume average of 0.12 million. Huntington Bancshares reported 1,044 shares stake.

Teachers Retirement System of The State of Kentucky lessened its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Amp Cap Limited stated it has 88,361 shares or 0.07% of all its holdings. 32,077 are held by Fort Point Capital Prns Ltd Liability. Sheets Smith Wealth has invested 0.22% in Alexion Pharmaceuticals, Inc.

TRADEMARK VIOLATION NOTICE: "Alexion Pharmaceuticals, Inc". (NASDAQ:ALXN) shares were sold by Franchini Indrani Lall. The current ratio looks at all the liquid and non-liquid assets compared to the company's total current liabilities. Dupont Capital Management Corp purchased a new position in Alexion Pharmaceuticals in the third quarter worth about $156,000. Sit Inv Inc holds 0.1% of its portfolio in Alexion Pharmaceuticals, Inc.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER